FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Puttagunta Sailaja		 2. Issuer Name and Ticker or Trading Symbol

BiomX Inc. [ PHGE ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Medical Officer
(Last)          (First)          (Middle)

C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2		 3. Date of Earliest Transaction (MM/DD/YYYY)

3/25/2020
(Street)

NESS ZIONA, L3 7414002
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Common Stock Options - Right to Buy $6.21 3/25/2020  A   67500     (1)3/25/2030 Common Stock 67500 $0 67500 (2)I See Footnote (3)
Explanation of Responses:
(1) The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years.
(2) Does not include 263,576 additional options previously granted to the Reporting Person which have different exercise prices and which vest on different schedules.
(3) The options are held by SPB Consulting LLC. The Reporting Person is the sole member of SPB Consulting LLC and may be deemed the indirect beneficial owner of the securities held by SPB Consulting LLC.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Puttagunta Sailaja
C/O BIOMX LTD.
7 PINHAS SAPIR ST., FLOOR 2
NESS ZIONA, L3 7414002

Chief Medical Officer
Signatures
/s/ Sailaja Puttagunta3/27/2020
**Signature of Reporting PersonDate
BiomX (AMEX:PHGE.U)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more BiomX Charts.
BiomX (AMEX:PHGE.U)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more BiomX Charts.